| Assessment Status | Full HTA submission received from Applicant |
| HTA ID | 23078 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Pembrolizumab (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy*. |
| Assessment Process | |
| Rapid review commissioned | 20/12/2023 |
| Rapid review completed | 24/01/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
| Full pharmacoeconomic assessment commissioned by HSE | 02/02/2024 |
| Pre-submission consultation with Applicant | 27/08/2024 |
| Full submission received from Applicant | 27/02/2025 |
*The Applicant is seeking reimbursement in a subgroup of the eligible population whose tumours express PD-L1 <50%.
